Reviewing Monopar Therapeutics (NASDAQ:MNPR) and TransCode Therapeutics (NASDAQ:RNAZ)

TransCode Therapeutics (NASDAQ:RNAZGet Free Report) and Monopar Therapeutics (NASDAQ:MNPRGet Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Risk and Volatility

TransCode Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares TransCode Therapeutics and Monopar Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TransCode Therapeutics N/A N/A -$18.55 million N/A N/A
Monopar Therapeutics N/A N/A -$8.40 million ($1.97) -21.23

Profitability

This table compares TransCode Therapeutics and Monopar Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TransCode Therapeutics N/A -649.03% -281.34%
Monopar Therapeutics N/A -107.21% -87.57%

Institutional and Insider Ownership

1.8% of Monopar Therapeutics shares are held by institutional investors. 2.8% of TransCode Therapeutics shares are held by insiders. Comparatively, 34.9% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for TransCode Therapeutics and Monopar Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics 0 0 1 0 3.00
Monopar Therapeutics 0 0 4 0 3.00

TransCode Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 101.21%. Monopar Therapeutics has a consensus target price of $43.00, suggesting a potential upside of 2.82%. Given TransCode Therapeutics’ higher probable upside, equities analysts clearly believe TransCode Therapeutics is more favorable than Monopar Therapeutics.

Summary

Monopar Therapeutics beats TransCode Therapeutics on 7 of the 8 factors compared between the two stocks.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo EspaƱol de InvestigaciĆ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.